FindMyRecallSubscribe
Class I: serious health riskTerminated

Hikma Pharmaceuticals Ketorolac Tromethamine Injection Recall

Ketorolac Tromethamine Injection, USP 30 mg/mL, packaged in 1 mL Single Dose Vials (NDC…

Hikma Pharmaceuticals USA Inc. · Cherry Hill, NJ

Risk level
Class I
Reported by FDA
Jan 22, 2020
Recall ID
D-0864-2020
Check your lot numberHow we source this data

Summary

Hikma Pharmaceuticals recalled Ketorolac Tromethamine Injection starting Dec 17, 2019. The FDA classified it as Class I (serious health risk) and published enforcement report D-0864-2020 on Jan 22, 2020. Reason: Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS). Status: Terminated.

Why it was recalled

Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)

Product description

Ketorolac Tromethamine Injection, USP 30 mg/mL, packaged in 1 mL Single Dose Vials (NDC 0641-6042-01), 25 vials/shelf-pack (NDC 0641-6042-25), For IV or IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.

Lot numbers, UPCs & expiration codes

Lot #: 038366, Exp. Date Mar 2020; 048365, 048367, Exp. Date Apr 2020; 078301, 078303, Exp. Date July 2020; 118358, Exp. Date Nov 2020; 029353, Exp. Date Feb 2021; 019413, Exp. Date Jan 2021

Where it was sold

Nationwide within the United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0864-2020
Classification
Class I
Status
Terminated
Recall initiated
Dec 17, 2019
FDA report date
Jan 22, 2020
Quantity
101,710 25 vials/shelf-pack
Recall type
Voluntary: Firm initiated
Recalling firm
Hikma Pharmaceuticals USA Inc.

Original FDA data

Every field from FDA enforcement report D-0864-2020, exactly as published.

Show all FDA fields
City
Cherry Hill
State
NJ
Status
Terminated
Country
United States
Event ID
84534
Address
2 Esterbrook Ln
Code information
Lot #: 038366, Exp. Date Mar 2020; 048365, 048367, Exp. Date Apr 2020; 078301, 078303, Exp. Date July 2020; 118358, Exp. Date Nov 2020; 029353, Exp. Date Feb 2021; 019413, Exp. Date Jan 2021
Postal code
08003-4002
Report date
Jan 22, 2020
Product type
Drugs
Recall number
D-0864-2020
Classification
Class I
Recalling firm
Hikma Pharmaceuticals USA Inc.
Product quantity
101,710 25 vials/shelf-pack
Termination date
Jun 9, 2021
Reason for recall
Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)
Voluntary / mandated
Voluntary: Firm initiated
Product description
Ketorolac Tromethamine Injection, USP 30 mg/mL, packaged in 1 mL Single Dose Vials (NDC 0641-6042-01), 25 vials/shelf-pack (NDC 0641-6042-25), For IV or IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.
Distribution pattern
Nationwide within the United States
Recall initiation date
Dec 17, 2019
Initial firm notification
Letter
Center classification date
Mar 2, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0864-2020, published Jan 22, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls